VIVUS Receives Consensus Rating of “Hold” from Brokerages (NASDAQ:VVUS)
Shares of VIVUS (NASDAQ:VVUS) have earned a consensus rating of “Hold” from the thirteen analysts that are covering the company, AR Network reports. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $7.64.
VIVUS (NASDAQ:VVUS) opened at 4.54 on Wednesday. VIVUS has a one year low of $4.44 and a one year high of $14.14. The stock has a 50-day moving average of $4.91 and a 200-day moving average of $5.58. The company’s market cap is $469.2 million.
VIVUS (NASDAQ:VVUS) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.03. The company had revenue of $21.90 million for the quarter, compared to the consensus estimate of $17.90 million. During the same quarter in the previous year, the company posted ($0.55) earnings per share. The company’s revenue for the quarter was up 298.2% on a year-over-year basis. On average, analysts predict that VIVUS will post $-0.99 earnings per share for the current fiscal year.
VIVUS, Inc is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.